Cargando…

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2

Since their discovery as drivers of proliferation, cyclin-dependent kinases (CDKs) have been considered therapeutic targets. Small molecule inhibitors of CDK4/6 are used and tested in clinical trials to treat multiple cancer types. Despite their clinical importance, little is known about how CDK4/6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pack, Lindsey R., Daigh, Leighton H., Chung, Mingyu, Meyer, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184839/ https://www.ncbi.nlm.nih.gov/pubmed/34099663 http://dx.doi.org/10.1038/s41467-021-23612-z

Ejemplares similares

Stress-mediated exit to quiescence restricted by increasing persistence in CDK4/6 activation
por: Yang, Hee Won, et al.
Publicado: (2020)

Altered G1 signaling order and commitment point in cells proliferating without CDK4/6 activity
por: Liu, Chad, et al.
Publicado: (2020)

Molecular docking analysis of piperine with CDK2,CDK4,Cyclin D and Cyclin T proteins
por: Rekha, Umapathy Vidhya, et al.
Publicado: (2020)

Stochastic Endogenous Replication Stress Causes ATR-Triggered Fluctuations in CDK2 Activity that Dynamically Adjust Global DNA Synthesis Rates
por: Daigh, Leighton H., et al.
Publicado: (2018)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Lineage specific composition of cyclin D–CDK4/CDK6–p27 complexes reveals distinct functions of CDK4, CDK6 and individual D‐type cyclins in differentiating cells of embryonic origin
por: Bryja, V., et al.
Publicado: (2008)

Cyclin K goes with Cdk12 and Cdk13
por: Kohoutek, Jiri, et al.
Publicado: (2012)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21
por: Colleoni, B, et al.
Publicado: (2017)

APC/C prevents non-canonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor-induced arrest
por: Mouery, Brandon L, et al.
Publicado: (2023)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
por: Zhang, Wengang, et al.
Publicado: (2023)

CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point
por: Bisteau, Xavier, et al.
Publicado: (2013)

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
por: Coxon, Christopher R., et al.
Publicado: (2016)

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
por: Johnston, Stephen, et al.
Publicado: (2023)

CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
por: Nardone, Valerio, et al.
Publicado: (2021)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

Temporal changes in cyclinD-CDK4/CDK6 and cyclinE-CDK2 pathways: implications for the mechanism of deficient decidualization in an immune-based mouse model of unexplained recurrent spontaneous abortion
por: Chang, Zhuo, et al.
Publicado: (2022)

Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
por: Matsumoto, M, et al.
Publicado: (1999)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Regulation of CDK4
por: Bockstaele, Laurence, et al.
Publicado: (2006)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Cdk2 and Cdk4 cooperatively control the expression of Cdc2
por: Berthet, Cyril, et al.
Publicado: (2006)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Caenorhabditis elegans Cyclin D/CDK4 and Cyclin E/CDK2 Induce Distinct Cell Cycle Re-Entry Programs in Differentiated Muscle Cells
por: Korzelius, Jerome, et al.
Publicado: (2011)

Nuclear Import of Cdk/Cyclin Complexes: Identification of Distinct Mechanisms for Import of Cdk2/Cyclin E and Cdc2/Cyclin B1
por: Moore, Jonathan D., et al.
Publicado: (1999)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
por: Sofi, Shazia, et al.
Publicado: (2022)

Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells
por: Zhang, Jiawei, et al.
Publicado: (2022)

Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding
por: Faber, Erik B., et al.
Publicado: (2023)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas
por: Hadjadj, Djihad, et al.
Publicado: (2017)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
por: Xu, Hanxiao, et al.
Publicado: (2017)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division
por: Clemm von Hohenberg, Katharina, et al.
Publicado: (2022)

Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
por: Majumdar, Abir, et al.
Publicado: (2021)

P1412: UNCOUPLING INK4 PROTEINS FROM CDK4/CDK6 IN HEMATOPOIETIC STEM CELLS
por: Schirripa, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_14lq2b9jj0uj2on973pfdqiaau